* While patients are implanted with the AB5000 with the goal of recovering the heart, there have been some instances in which, after giving a patient's heart a full opportunity to recover, doctors have determined that recovery will not occur. Nearly thirty percent of survivors have received heart transplants after it was determined that native heart function would not return; their average duration of support on the AB5000 was nearly 40 days.
* 20 percent of all AB5000 patients were supported following AMI-
Cardiogenic shock.
* 47 percent of all AB5000 patients required support on both sides of the heart.
* Nineteen patients have ambulated while on AB5000 support, walking
hospital grounds as well as using treadmills and stationary bicycles.
The AbioCor
The AbioCor is the world’s first completely self-contained replacement heart. A product of three decades of research, development and testing, the AbioCor is central to ABIOMED’s mission to make real the day when heart failure need not mean the end of life or the ability to enjoy life. Designed to fully sustain the body's circulatory system, the AbioCor is intended for end-stage heart failure patients whose other treatment options have been exhausted.
In 2001, ABIOMED made history when Mr. Robert Tools, a 58-year-old telephone company employee and teacher suffering from end stage heart failure was successfully implanted with the first AbioCor. The initial clinical trial is continuing with the aim of gaining approval to market the AbioCor to support patients with irreversible end-stage heart failure. The company also recently submitted to the FDA for commercial approval for the AbioCor under a Humanitarian Device Exemption.
ABIOMED is also working on the next generation implantable replacement heart, the AbioCor II. Incorporating technology both from ABIOMED and Penn State, the AbioCor II is smaller and is being designed with a goal of five year reliability.
Article comments
1 - Aaman
This is an advert - not really a blogpost. Interesting product, though.
2 - Shark
This guy has polluted the site before. He uses it for MARKETING. It's cheap.
Go away, motherfucker.
3 - Aaman
Let's beat him at his own game: some numbers about this company:
EPS: -0.26
Moving Average Convergence/Divergence (MACD) indicates a Bearish Trend.
Chart pattern indicates a Strong Downward Trend.
Relative Strength is Bearish.
Up/Down volume pattern indicates that the stock is under Distribution.
The 50 day Moving Average is falling which is Bearish.
Zacks Rank for ABIOMED INC (ABMD):
[ 4 ] SELL Stocks with a Zacks Rank of 4 are considered a SELL and are the second lowest rating given by Zacks.
Here is a graph of the stock, showing the insider sales through the last year - note the pattern and lack of insider purchases.
Here is an interesting article about their attempts on avoiding publicity - a news blackout on their heart device
4 - Temple Stark
This does read exaclt like spam I get.
Is this a paid spot? Because that's what Blogads are for.
5 - bhw
I'll check with Eric on this one....
6 - Robert T DeMarco
Aaman, I would agree with your technical analysis at this point in time. However, the black out on the mechanical heart is due to their application for the humanitarian device exception. The company announced sometime ago they were suspending testing of this device concurrent with their application.
The AB5000 business is growing fast and they have only gotten to about one percent of the addressable market.
As I stated clearly at the top of the post. This was intended for information only and I own the stock. A good investor looking for ideas could decide to investigate the story and then buy or short the stock. So you or anyone else is free to do as they see fit.
I am not a stockbroker nor do I work for the company. I do have an investor blog.
My real intention was to bring this story into the awareness of investors looking for ideas. This stock is not widely covered by research analyst at this time because the float is small and the volume is small. The Company did present at a Piper Jaffrey conference yesterday.
Nevertheless, the company has intriguing technology and a world class management team.
On the technical front you could have made the same comment when the stock dropped from the $14.00 area to the $8.50 area and you would have been correct for a time. But the methodolgy you described is more suited for short term trading from my point of view.
I feel the story behind this story is fundamental. Because both markets are enormous. But, that is my opinion on this one.
Perhaps we can come back to this post in a few months and discuss the price and the developments in the company at that time.
Meanwhile, I am open to new ideas on emerging companies if you have some. You never know where the next good investing idea is going to come from or who is going to supply the idea.
I am sorry I offended Shark. Please feel free to ignore me. Nevertheless, its OK by me if you prefer to spit venom.
Bob
7 - Aaman
Robert, thank you for your comments. I myself am a long term investor, but prefer to play it safe by only investing in "Foolish Four" type stocks and Type 1 stocks. This does not fit the bill - yet. Like I mentioned, interesting product.